A Phase 0 of Neoadjuvant Lapatinib in Infiltrative Bladder Carcinoma Before Cystectomy (LAPAINBLAD)
Pilot Study of Lapatinib (Tyverb®) in Neoadjuvant Treatment for Patients With Locally Bladder Carcinoma Before Cystectomy
Sponsor: University Hospital, Bordeaux
Terminated
The rythm of enrollment was not compatible with the objective of recruitement in the research.
Other terminated trials from University Hospital, Bordeaux
Other Bladder Carcinoma trials with similar outcome
This EARLY_PHASE1 trial investigates Bladder Carcinoma and Cystectomy and is currently terminated or withdrawn. University Hospital, Bordeaux leads this study, which shows 6 recorded versions since 2011 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
6 versions recorded-
Sep 2024 — Present [monthly]
Terminated EARLY_PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Terminated EARLY_PHASE1
-
Jan 2021 — Jul 2024 [monthly]
Terminated EARLY_PHASE1
-
Jun 2018 — Jan 2021 [monthly]
Terminated EARLY_PHASE1
-
Feb 2017 — Jun 2018 [monthly]
Terminated EARLY_PHASE1
Phase: Phase 0 → EARLY_PHASE1
▶ Show 1 earlier version
-
Jan 2017 — Feb 2017 [monthly]
Terminated Phase 0
First recorded
Jan 2011
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- University Hospital, Bordeaux
For direct contact, visit the study record on ClinicalTrials.gov .